Printer Friendly

Analysis of T Cell Subsets in Adult Primary/Idiopathic Minimal Change Disease: A Pilot Study.

1. Introduction

Primary minimal change disease (MCD) is a common cause of idiopathic nephrotic syndrome. Histopathologically, it is characterised by the apparent lack of abnormalities on light or immunofluorescence microscopy but effacement of foot processes on electron microscopy. It is believed that podocyte injury underlies the fundamental dysfunction in this disease. MCD is, therefore, also classified as a type of primary podocytopathy [1]. In this condition, disruption of the glomerular filtration barrier leads to increased glomerular permeability to proteins, causing severe urinary loss of proteins including albumin, immunoglobulins, complement, lipid-binding proteins, and clotting factors. The ensuing complications include hypoalbuminemia, generalised oedema, and malnutrition, as well as predisposition of patients to risk of infection, thrombotic events, and dyslipidemia.

Although the mechanisms underlying podocyte injury may include both nonimmunological factors and immunological factors [2, 3], they remain largely speculative and poorly understood. An interesting breakthrough in the science of MCD was finding an association of high serum levels and overexpression on podocytes of a sialic acid-deficient form of the glycoprotein angiopoietin-like 4 with several clinical, functional, and histopathological features of human and murine MCD, including the severity of proteinuria, effacement of podocyte foot processes, loss of glomerular basement membrane charge, and sensitivity to corticosteroids therapy [4]. Auspiciously, the treatment with N-acetyl-D-mannosamine (a sialic acid precursor) significantly improved proteinuria in the affected animals. On the other hand, immune factors, in particular T cell dysfunction and the release of circulating glomerular permeability factors (which are putative cytokines), are among the most commonly implicated contributing immunological alterations behind the occurrence of MCD [5-7]. Given the well-known role of [Foxp3.sup.+] regulatory T (Treg) cells as the master moderators of immune responses [8, 9], it is conceivable that a dysfunction of Treg cell biological functions or a numerical deficiency may contribute significantly to the pathogenesis of MCD.

[Foxp3.sup.+] Treg cells play a central role in the maintenance of immune homeostasis. They moderate ongoing immune responses by controlling the activation, proliferation, and effector functions of various cells of the innate defence and the immune systems. Of note, they can be divided into two main subsets, thymic and peripheral [Foxp3.sup.+] Treg cells, having different origins as well as distinct and complementary functions in both physiological and pathological immune situations [10-12]. Thymic [Foxp3.sup.+] Treg cells acquire their immunoregulatory capacities in the thymus while being selected by the self-major histocompatibility complex molecules and self-antigens present in the thymus. The role of thymic [Foxp3.sup.+] Treg cells in the periphery, therefore, appears to be maintenance of immune tolerance through modulation of activation, differentiation, and proliferation of potential autoreactive T cell clones [13,14]. On the other hand, peripheral [Foxp3.sup.+] Treg cells derive from stimulation of naive T cells with foreign antigens or altered self-antigens in secondary lymphoid organs and inflamed tissues [9]. The generation of peripheral [Foxp3.sup.+] Treg cells is driven by the concomitant activation of effector T (Teff) cells, which serve as a source of IL-2 and other permissive cytokines that are necessary for their development [15, 16]. Thus, the role of peripheral [Foxp3.sup.+] Treg cells appears to be the control of ongoing immune responses to foreign antigens and self-antigens not expressed in the thymus, thereby preventing inappropriate inflammatoryresponses and autoimmune disorders triggered by inflammation or infection where T helper (Th)17, Th1, and cytotoxic T cells (CTL) are believed to play an active role [11, 13,14,17]. A dysfunction of [Foxp3.sup.+] Treg cells, encompassing both numerical and functional imbalance between [Foxp3.sup.+] Treg cells and Teff cells, may lead to a disturbance of immune homeostasis that potentially contributes to disease pathogenesis in MCD.

Indeed, previous studies have suggested such dysfunction of [Foxp3.sup.+] Treg cells in the pathogenesis of primary MCD. A study performed on 38 children with primary MCD or focal segmental glomerulosclerosis reported a lesser infiltration of [Foxp3.sup.+] T cells in affected patients compared to controls [18].

Another study performed on 21 adults with primary MCD demonstrated decreased suppressive capacity of [Foxp3.sup.+] Treg cells, although patients had similar numbers of circulating [Foxp3.sup.+] Treg cells in comparison with controls [19]. In another report, 21 children with steroid-resistant nephrotic syndrome had increased ratios of circulating interferon- (IFN-) gammasecreting Th1 cells and IL-4-secreting Th2 cells over [Foxp.sup.3+] Treg cells when compared to 22 children with steroidsensitive nephrotic syndrome in clinical remission and 14 healthy controls [20]. The interplay between Th17 cells and [Foxp3.sup.+] Treg cells has also been reported in two studies. One study showed an increase in circulating Th17 cells over Treg cells in 25 adult patients with primary MCD when compared to healthy controls, which also correlated with severity of proteinuria [21]. The other study performed on 36 children with idiopathic nephrotic syndrome demonstrated an increase in circulating Th17 cells over Treg cells when compared to healthy controls, which was associated with an increase in intrarenal IL-17 expression [22].

Our primary aim was to confirm whether a similar immune imbalance of T cell subsets is a feature of primary MCD in our population. We focused primarily on the numerical balance of Th17 and cytotoxic cells [comprising

CTL and natural killer (NK) cells] over the [Foxp3.sup.+] Treg subset in kidney tissue by immunohistochemistry, using their relative ratio as an arbitrary measure of such balance. We have described our tissue results as a case series due to the lack of normal kidney tissue for comparison. We also detected and quantified different Teff cells in the peripheral blood of patients using flow cytometry but focused our main analysis on Th17 cells, CD8+ T cells (a surrogate phenotype for CTL), and [Foxp3.sup.+] Treg cells. We compared our findings in the peripheral blood of these patients to our observations in healthy controls. Finally, we explored correlations between our chosen immune parameters and clinical outcomes, including deterioration of kidney function and proteinuria, as well as time to complete clinical remission. Therefore, this is a pilot descriptive study reporting the observed frequencies of different immune cell subsets in kidney tissue and peripheral blood of MCD patients and their association with clinical outcomes.

2. Material and Methods

2.1. Study Design and Patients. This was a single-centre prospective study in a cohort of 9 consecutive patients aged 21-80 years with new-onset biopsy proven MCD thought to be idiopathic in nature. Patients were recruited at the Department of Renal Medicine of the Singapore General Hospital (SGH) between 1 January 2012 and 31 March 2014 at the time when native kidney biopsy was performed for the investigation of new-onset nephrotic syndrome and followed for up to 48 months for outcomes analysis. Healthy individuals were recruited to serve as a control group for many of the comparisons in the peripheral blood studies.

Signed informed consent was taken from all participants and our protocol was approved by our Centralised Institutional Review Board (Approval number 2009/672/E).

2.2. Exclusion Criteria. HIV infection, history of haematological malignancies, children, pregnant women, poor cognitive capacity, prisoners, and inability to understand the research protocol and give consent were the exclusion criteria.

2.3. Clinical Data. Baseline demographic and clinical characteristics were retrieved from patient hard-copy case notes and electronic medical records. Use and type of immunosuppressants prescribed were also recorded.

2.4. Routine Laboratory Investigations. Serum creatinine was measured and proteinuria was quantified by means of either the urine protein to creatinine ratio or a 24-hour collection of total urinary protein. Calculated estimated glomerular filtration rate (GFR) was obtained through the modified diet in renal disease (MDRD) equation. All laboratory parameters were retrieved prospectively from electronic medical records at 6-month intervals from the time of native kidney biopsy up to 48 months of follow-up. All laboratory investigations were conducted at the SGH's clinical laboratory, which is accredited by the College of American Pathologists.

2.5. T Cell Subset and B Cell Detection in Native Kidney Biopsies by Immunohistochemistry. Immunohistochemistry for detection of T cell subsets and B cells in native kidney tissue biopsies was performed at the laboratories in both the Renal Department and Department of Pathology of the SGH. In brief, sections prepared from formalin-fixed and paraffin-embedded kidney tissue specimens were stained with monoclonal antibodies conjugated with either horseradish peroxidase or alkaline phosphatase and directed against different phenotypic markers, including CD4 (used as a surrogate marker of [CD4.sup.+] T cells), CD8 (used as marker of CD8+ T cells), CD19 (used as marker of B cells), IL-17 (used as marker of IL17-secreting Th17 cells), granzyme B (a marker of cytotoxic cells, comprising both CTL and NK cells), and Foxp3 (used as a surrogate marker of Treg cells) using an automatic stainer machine. The binding of the different antibodies onto the kidney tissue samples was revealed using the respective chromogenic substrates for those enzymes. Isotype-matched antibodies were used as negative controls. Tonsil tissue served as positive control. Staining was visualized and measured by light microscopy semiquantitatively as percentage of infiltration for [CD4.sup.+], [CD8.sup.+], and [CD19.sup.+] cells and expressed as number of cells per [mm.sup.2] of kidney biopsy (cell density) by adjusting to biopsy surface area measured by Olympus CellSens software for [Foxp3.sup.+], [IL-17.sup.+], or granzyme [B.sup.+] cells.

2.6. Phenotypic Analysis of T Cell Subsets by Flow Cytometry. The quantification of total [CD3.sup.+] T cells, [CD4.sup.+] T cells, [CD8.sup.+] T cells, and [CD19.sup.+] B cells in peripheral whole blood of patients and healthy controls was performed by flow cytometry using a BD LSR II machine available at the haematology laboratory of the SGH, using fluorochrome-labelled monoclonal antibodies against CD45, CD3, CD4, CD8, and CD19. The quantification of [CD4.sup.+][CD25.sup.+][Foxp3.sup.+]Treg cells, [CD4.sup.+][CD161.sup.+] Th17 cells, [CD4.sup.+][CD45RA.sup.-] memory T cells, [CD4.sup.+][CD45RA.sup.+] naive T cells, [CD8.sup.+][CD45RA.sup.-] memory T cells, [CD8.sup.+][CD45RA.sup.+] naive T cells, C[D3.sup.+][CD56.sup.+] natural killer T (NKT) cells, [CD3.sup.+][TCRd1.sup.+] gamma-delta T cells, [CD3.sup.+][TCRd2.sup.+] gamma- delta T cells, [CD4.sup.-][CD161.sup.+][TCRa7.2.sup.+] mucosal-associated invariant T (MAIT) cells, and [CD3.sup.-][CD56.sup.+] natural killer (NK) cells in stored peripheral blood mononuclear cells of patients and healthy controls was performed by flow cytometry using a BD LSR II machine available at the Singapore Immunology Network, using fluorochrome-labelled monoclonal antibodies against different phenotypic markers including CCR6, CD3, CD4, CD5, CD8, CD14, CD19, CD25, CD27, CD28, CD39, CD45RA, CD45RO, CD49d, CD56, CD127, CD152, CD161, GARP, TCRa7.2, TCRd1, and TCRd2. All the stained cells were acquired in a 20-colour flow cytometer, and the results were analysed using FlowJo v9.5 software. For compensation and calibration purposes, commercially available fluorochrome-labelled beads were used as controls. Percentages of marker-expressing cells were reported and adjusted as percentage of the lymphocyte counts. Absolute numbers of these T cell subsets were obtained by adjusting the percentages to the lymphocyte counts obtained through measuring the full blood count in the SGH's clinical laboratory.

2.7. Statistical Analysis. Being an exploratory, descriptive study in consecutively recruited patients during the allowed recruitment period, sample size was not calculated. Descriptive statistics were used to display our results obtained from our immunohistochemical investigations. No comparison with healthy control kidney tissue was possible. The different lymphocyte and T cell subset percentages and ratios in peripheral blood were compared between the patients with primary MCD and the healthy controls using the Mann-Whitney U test. Spearman correlation was used to assess strength of association of lymphocyte and T cell subset percentages and numbers in kidney tissue and peripheral blood with different clinical outcomes, including changes in serum creatinine, MDRD GFR, and proteinuria, as well as time to complete clinical remission, doubling of creatinine, and need for dialysis. All analyses were performed using SAS V9.3 software (SAS Inc., Cary, NC, USA).

3. Results

Nine patients with primary MCD were included in this study. All had their native kidney biopsy specimens tested by immunohistochemistry for detection of different T cell subsets and B cells. The obtaining of normal kidney tissue (or a surrogate tissue for normality) as control for our immunohistochemical studies was not possible. Eight patients provided blood sample for measurement of different T cell subsets in peripheral blood by flow cytometry. As many as twelve healthy individuals served as controls for our immune cell detection in peripheral blood by flow cytometry. Baseline demographic and clinical characteristics of recruited patients are shown in Table 1. Most patients were young Chinese males with full-blown nephrotic syndrome and not taking steroids or immunosuppression at the time of biopsy. Detailed clinical parameters for each patient are presented in Table 2.

Figure 1 shows a phenotypic panel (by immunohistochemistry) of several T cell subsets and B cells in a patient with primary MCD. The pictures were taken at an area of moderate infiltration of both T and B cells for demonstration of our detection capability as the infiltrate was scarce and the overall staining was discrete in most patients, but sufficient for subset identification and quantification. The cell infiltrate in MCD patients was composed mainly of [CD4.sup.+] and [CD8.sup.+] T cells with a small population of B cells. The median percentage of infiltration of [CD4.sup.+] T cells, [CD8.sup.+] T cells, and [CD19.sup.+] B cells, and the median cell density (cells per square millimeter of kidney biopsy) of the [IL-17.sup.+] cells (Th17 cells), granzyme [B.sup.+] cytotoxic cells (comprising both CTL and NK cells), and [Foxp3.sup.+] cells (Treg cells) is plotted in Figure 2. We observed higher cell densities of Th17 cells and cytotoxic cells when compared to [Foxp3.sup.+] Treg cells. As a consequence, the ratios of Th17 cells over [Foxp3.sup.+] Treg cells and cytotoxic cells over [Foxp3.sup.+] Treg cells, an arbitrary measurement of the numerical balance between these subsets, were increased. We had no access to normal kidney tissue for comparison of our findings and to investigate whether our observed frequencies and ratios were different to the ones observed in healthy individuals.

In peripheral blood we measured the percentage (from the lymphocyte count) and the absolute numbers per microlitre of blood of circulating [CD3.sup.+] T cells, [CD4.sup.+] T cells, [CD8.sup.+] T cells, [CD19.sup.+] B cells, and monocytes, as well as [CD4.sup.+][CD25.sup.+][Foxp3.sup.+] Treg cells, [CD4.sup.+][CD161.sup.+] Th17 cells, [CD4.sup.+][CD45RA.sup.-] memory T cells, [CD4.sup.+][CD45RA.sup.+] naive T cells, [CD8.sup.+][CD45RA.sup.-] memory T cells, [CD8.sup.+][CD45RA.sup.+] naive T cells, [CD3.sup.+][CD56.sup.+] NKT cells, [CD3.sup.+][TCRd1.sup.+] gamma-delta T cells, [CD3.sup.+][TCRd2.sup.+] gamma-delta T cells, [CD4.sup.-][CD161.sup.+][TCRa7.2.sup.+] MAIT cells, and [CD3.sup.-][CD56.sup.+] NK cells. Figure 3 illustrates some of the T cell subsets detected using multicolour flow cytometry in a representative patient with primary MCD. In peripheral blood, we found significantly higher percentages of total [CD3.sup.+] T cells (p = 0.0092) and of total [CD8.sup.+] T cells (p = 0.0358) in primary MCD patients when compared to healthy controls (Figures 4(b) and 4(f)), but there was no significant difference in the percentages or numbers of naive and memory [CD8.sup.+] T cells between the two groups. [Foxp3.sup.+] Treg cells were not significantly reduced in primary MCD patients in comparison to the healthy controls (Figures 4(o) and 4(p)). On the other hand, the number of Th17 cells was significantly reduced in primary MCD patients in comparison with controls (p = 0.0333; Figure 4(q)). There were no statistically significant differences in the other T cell subsets or immune cells studied between primary MCD and the healthy controls (Figure 5), except for the finding of lower circulating NK cells in patients with primary MCD. Finally, there were no differences in the calculated ratios of circulating Th17 cells over [Foxp3.sup.+] Treg cells or circulating memory [CD8.sup.+] T cells over [Foxp3.sup.+] Treg cells (Figure 6).

We correlated selected immune cellular parameters with clinical outcomes to address any potential clinical meaning, as an exploratory analysis. Table 3 shows the statistically significant correlations found between the circulating and infiltrating immune subsets with serum creatinine, MDRD GFR, and proteinuria (at different time points during followup), as well as time to complete clinical remission in our exploratory analyses. Complete clinical remission was achieved in these patients with a median time of 28 days (Figure 7) with subsequent stabilisation of serum creatinine. No patient had a doubling of creatinine or underwent dialysis. In relationship with our original hypothesis, at disease onset, the number of circulating [CD8.sup.+] T cells correlated positively with serum creatinine (Figure 8(a)) and negatively with MDRD GFR (Figure 8(b)), the percentage of kidney tissue infiltrating [CD4.sup.+] T cells (Figure 8(c)) and the percentage of circulating naive [CD8.sup.+] T cells (Figure 8(d)) correlated positively with proteinuria, and the ratio of tissue cytotoxic over [Foxp3.sup.+] Treg cells correlated negatively with MDRD GFR (Figure 8(e)).

4. Discussion

Although the immunopathogenesis of primary MCD is complex and remains largely nondeciphered, it has been proposed that disturbances in the immune balance between Teff cells and [Foxp3.sup.+] Treg cells play a potential pathogenic role [23]. This pilot study was conducted to describe the relative frequencies of different Teff cells and [Foxp3.sup.+] Treg cells, in both tissue and peripheral blood, as an arbitrary measurement of their immune balance in primary MCD. Despite the small sample size, its main strength is the combining of tissue data with detailed phenotypic analysis of different immune cell subsets in peripheral blood as well as with clinical parameters. To the best of our knowledge, this has not been attempted in previous studies.

In tissue, we found the overall T cell infiltration into the kidney interstitium of patients with primary MCD to be minimal (Figure 2). Our finding that kidney interstitial infiltrates of these primary MCD patients were composed mainly of T cells rather than B cells is in keeping with the notion that primary MCD is fundamentally a T cell disorder. In addition, there appeared to be a relative deficiency of [Foxp3.sup.+] Treg cells over Th17 cells and cytotoxic cells. Our study showed that the ratios of Th17 cells over [Foxp3.sup.+] Treg cells, as well as cytotoxic cells over [Foxp3.sup.+] Treg cells, were elevated (arbitrarily deciding a ratio above 1). Although ideally infiltrates in normal healthy subjects would be used for comparison, it was ethically unachievable in our descriptive study. Other studies have compared their observations with those from living donor kidney tissue or patients with thin-membrane disease [18,24]. At the SGH, no biopsy is obtained preimplantation in living donors, and none of the patients recruited in our parallel studies had thin-membrane disease as diagnosis. In those studies, healthy or "normal" controls were found also to have a scarce cellular infiltrate, which could be or not comparable to that of our patients with MCD. As a consequence, in this paper, we are mainly describing and partially dissecting phenotypically the observed infiltrate and reporting their relative frequencies, which is a commonly encountered way to assess immune balance. But we do accept that this is an arbitrary and imperfect way to assess immune balance, especially when in vivo a complex functional and numerical interplay of the different immune arms activated or dysfunctional in several human disorders, rather than just a numerical balance, is taking place. However, that interplay can only be assessed with a multidimensional interrogation of the functional phenotypes present in disease states, as well as a detailed assessment of the hierarchy of involved cellular and molecular interactions, but this was beyond the scope and reach of our study design and aims. In addition, our findings are consistent with published data that demonstrates a possible deficiency of tissue-infiltrating [Foxp3.sup.+] Treg cells in primary MCD [18]. In addition, in a study reported in 2002, gene expression for granzyme B was detected intrarenally in 2 of 7 children with minimal change disease [25].

Concordant with published observations [19], our primary MCD patients displayed similar numbers of circulating [Foxp3.sup.+] Treg cells in comparison with healthy controls. However, counter to our hypothesis and the two reports previously mentioned [21, 22], we did not observe an increased ratio of circulating Th17 cells over [Foxp3.sup.+] Treg cells in patients with primary MCD in comparison to healthy controls. It is possible that these discrepant observations were due to the different technological approaches to detect Th17 cells. We used CD161 as a surrogate marker for Th17 cells (on [CD3.sup.+][CD4.sup.+] T cells) and we observed a decreased number of circulating Th17 cells in the patients with primary MCD in comparison to healthy controls. On the contrary, those authors based their detection on intracytoplasmic IL-17 expression, which indeed could be a more reliable marker. However, in those studies, the detection of IL-17-expressing cells required in vitro stimulation of T cells, which in our opinion (based on our unpublished observations with CyTOF mass cytometry in a different project in kidney transplantation) would likely overrepresent the actual frequencies of this subpopulation in vivo. Irrespective of this possibility, our tissue and peripheral blood results mirror themselves as we observed an apparent reduction of both infiltrating and circulating Th17 cells, implying that our observation not necessarily reflects technological difference but possibly a characteristic of this condition. Once again this is not conclusive as we lack a tissue control for comparison.

A technical limitation worth mentioning in our study, inherent of single-staining immunohistochemistry using surrogate cell markers, is the assumption that all the [CD4.sup.+] expressing cells were [CD4.sup.+] T cells, all the [Foxp3.sup.+] cells were Treg cells, and all the granzyme [B.sup.+] cells were CTL and NK cells. Immunofluorescence could have circumvented this limitation, which can be considered in subsequent grant applications.

It was interesting to observe some degree of association of our immune parameters with clinical features at presentation and with disease outcomes. Most of our patients achieved complete clinical remission promptly after initiation of steroid therapy and none doubled serum creatinine levels or required dialysis. Therefore, we focused our clinical outcomes analysis on levels of proteinuria and kidney function at disease onset and on time to clinical remission. In tune with our overall hypothesis, we found associations of infiltrating [CD4.sup.+] T cells and circulating [CD8.sup.+] T cells with higher proteinuria at onset and also correlation of circulating [CD8.sup.+] T cells and the infiltration ratio of cytotoxic cells over [Foxp3.sup.+] Treg cells with worse kidney function at presentation. Overall, these observations appear to support the long-standing notion that primary MCD could be a T cell-mediated disorder or that T cell dysfunction could play a significant role in its pathogenesis. However, these observations arose from exploratory analyses in a limited number of cases and should be taken with reserve. Nevertheless, we are reporting them for potential hypothesis-generation purposes rather than to suggest conclusions from them.

Overall, our results show that a numerical imbalance of different immune subsets, in particular a deficiency of [Foxp3.sup.+] Treg cells or a dominance of effector Th17 cells and cytotoxic cells, could be a characteristic of primary MCD. However, larger confirmatory studies looking into physiopathogenic mechanisms are necessary.

5. Conclusion

Primary MCD is an important cause of idiopathic nephrotic syndrome in adults. Different immune subsets can be detected in the renal interstitium of MCD patients, where a relative numerical abundance of Th17 cells and cytotoxic cells over [Foxp3.sup.+] Treg cells appears to be a characteristic of this condition. Although our observations are preliminary, they enhance the current limited knowledge on this topic, and although our paper does not provide functional data, our findings could incite further detailed studies to assess more mechanistically the so-called immune imbalance between [Foxp3.sup.+] Treg and Teff cells and its contribution in the pathogenesis of podocyte injury in primary MCD. A better understanding of the immunopathogenesis of primary MCD is necessary for the improvement of our current diagnostic armamentarium and the development of more targeted immunotherapy, which might potentially involve T cell subset modulation.
Abbreviations

CTL:    Cytotoxic T lymphocyte
GFR:    Glomerular filtration rate
IFN:    Interferon
MCD:    Minimal change disease
MDRD:   Modified diet in renal disease
MAIT:   Mucosal-associated invariant T
NK:     Natural killer
NKT:    Natural killer T
SGH:    Singapore General Hospital
Teff:   Effector T
Th:     T helper
Treg:   Regulatory T.


Additional Points

Summary. Primary minimal change disease is a common cause of idiopathic nephrotic syndrome in adults. Infections, certain environmental factors, and T cell dysfunction with increased levels of a soluble glomerular permeability factor have been proposed to play a central role in the pathogenesis of this condition. Therefore, a dysfunction, or a relative deficiency of [Foxp3.sup.+] regulatory T cells over effector T cells, could be implicated in its immunopathogenesis. We present here a pilot phenotypic analysis of the major T cell subsets infiltrating the kidney and in the peripheral blood of adult patients suffering from primary minimal change disease. An apparent numerical dominance of T helper 17 cells and cytotoxic cells over [Foxp3.sup.+] Treg cells was detected in the renal interstitium in primary/idiopathic minimal change disease, but we had no control normal kidney tissue for comparison. In peripheral blood, on the other hand, we observed an increase in the circulating total [CD8.sup.+] T cells in patients with minimal change disease. These results suggest that in primary/idiopathic minimal change disease, a relative numerical dominance of effector over regulatory T cells can be observed in kidney tissue and peripheral blood. However, larger confirmatory studies are necessary.

https://doi.org/ 10.1155/2017/3095425

Ethical Approval

The study protocol was approved by the Centralised Institutional Review Board of SingHealth, Singapore (Approval no. 2009/672/E).

Consent

Signed informed consent was taken from all participants before being subjected to a native kidney biopsy, which was clinically indicated and not an experimental procedure in our protocol.

Disclosure

Deidentified data was shared among few of the authors for the purpose of data analysis. No data was shared to third parties.

Conflicts of Interest

There are no conflicts of interest among the authors or the participating institutions, and the authors do not have any financial relationships to disclose.

Authors' Contributions

Francisco Salcido-Ochoa designed the study, revised all the collected data, analysed and plotted the data, and wrote and revised the paper; Susan Swee-Shan Hue analysed histopathological data and revised the paper; Doreen Haase designed the study and analysed the flow cytometry data; Jason Chon Jun Choo provided clinical advice and revised the paper; Nurhashikin Yusof performed the flow cytometry experiments and collected clinical data; Reiko Lixiang Li performed the immunohistochemistry experiments and collected clinical data; John Carson Allen Jr. performed and supervised statistical analysis and revised the paper; Jabed Iqbal analysed histopathological data and revised the paper; Alwin Hwai Liang Loh analysed histopathological data and revised the paper; Olaf Rotzschke designed the study, provided basic science advice, and revised the paper.

Acknowledgments

The authors would like to thank their research sponsors, SingHealth Foundation (Grant no. SHF/FG398P/2008) and the Medicine Academic Clinical Program under the SingHealth-Duke/National University of Singapore Joint Partnership, and Ms. Rachel Liew, their library technician, for helping them in getting the least accessible references.

References

[1] L. Barisoni, H. W. Schnaper, and J. B. Kopp, "A proposed taxonomy for the podocytopathies: a reassessment of the primary nephrotic diseases," Clinical Journal of the American Society of Nephrology, vol. 2, no. 3, pp. 529-542, 2007.

[2] G. Cara-Fuentes, W. L. Clapp, R. J. Johnson, and E. H. Garin, "Pathogenesis of proteinuria in idiopathic minimal change disease: molecular mechanisms," Pediatric Nephrology, vol. 31, no. 12, pp. 2179-2189, 2016.

[3] C. Dossier, A. Jamin, and G. Deschenes, "Idiopathic nephrotic syndrome: the EBV hypothesis," Pediatric Research, vol. 81, pp. 233-239, 2016.

[4] L. C. Clement, C. Avila-Casado, C. Mace et al., "Podocyt-esecreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome," Nature Medicine, vol. 17, no. 1, pp. 117-122, 2011.

[5] R. J. Shalhoub, "Pathogenesis of lipoid nephrosis: a disorder of T cell function," The Lancet, vol. 2, no. 7880, pp. 556-560, 1974.

[6] E. Schnenberger, J. H. Ehrich, H. Haller, and M. Schiffer, "The podocyte as a direct target of immunosuppressive agents," Nephrology Dialysis Transplantation, vol. 26, no. 1, pp. 18-24, 2011.

[7] J. G. Van Den Berg, J. Aten, M. A. Chand et al., "Interleukin-4 and interleukin-13 act on glomerular visceral epithelial cells," Journal of the American Society of Nephrology, vol. 11, no. 3, pp. 413-422, 2000.

[8] S. Sakaguchi, N. Sakaguchi, M. Asano, M. Itoh, and M. Toda, "Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases," Journal of Immunology, vol. 155, no. 3, pp. 1151-1164, 1995.

[9] S. Sakaguchi, T. Yamaguchi, T. Nomura, and M. Ono, "Regulatory T cells and immune tolerance," Cell, vol. 133, no. 5, pp. 775-787, 2008.

[10] M. Miyara, Y. Yoshioka, A. Kitoh et al.," Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor," Immunity, vol. 30, no. 6, pp. 899-911, 2009.

[11] A. D. Campbell and M. A. Koch, "Phenotypical and functional specialization of FOXP3+ regulatory T cells," Nature Reviews Immunology, vol. 11, no. 2, pp. 119-130, 2011.

[12] Y. Ding, J. Xu, and J. S. Bromberg, "Regulatory T cell migration during an immune response," Trends in Immunology, vol. 33, no. 4, pp. 174-180, 2012.

[13] C. Benoist and D. Mathis, "Treg cells, life history, and diversity," Cold Spring Harbor Perspectives in Biology, vol. 4, no. 9, article a007021, 2012.

[14] J. A. Bluestone and H. Bour-Jordan, "Current and future immunomodulation strategies to restore tolerance in autoimmune diseases," Cold Spring Harbor Perspectives in Biology, vol. 4, no. 11, 2012.

[15] W. Chen, W. Jin, N. Hardegen et al., "Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3," The Journal of Experimental Medicine, vol. 198, no. 12, pp. 1875-1886, 2003.

[16] I. Apostolou and H. Von Boehmer, "In vivo instruction of suppressor commitment in naive T cells," Journal of Experimental Medicine, vol. 199, no. 10, pp. 1401-1408, 2004.

[17] M. A. Curotto de Lafaille, N. Kutchukhidze, S. Shen, Y. Ding, H. Yee, and J. J. Lafaille, "Adaptive Foxp3+ Regulatory T Cell-Dependent and -Independent Control of Allergic Inflammation," Immunity, vol. 29, no. 1, pp. 114-126, 2008.

[18] K. Benz, M. Buttner, K. Dittrich, V. Campean, J. Dotsch, and K. Amann, "Characterisation of renal immune cell infiltrates in children with nephrotic syndrome," Pediatric Nephrology, vol. 25, no. 7, pp. 1291-1298, 2010.

[19] C. Araya, L. Diaz, C. Wasserfall et al., "T regulatory cell function in idiopathic minimal lesion nephrotic syndrome," Pediatric Nephrology, vol. 24, no. 9, pp. 1691-1698, 2009.

[20] A. Jaiswal, N. Prasad, and V. Agarwal, "Regulatory and effector T cells changes in remission and resistant state of childhood nephrotic syndrome," Indian Journal of Nephrology, vol. 24, no. 6, pp. 349-355, 2014.

[21] L.-L. Liu, Y. Qin, J.-F. Cai et al., "Th17/Treg imbalance in adult patients with minimal change nephrotic syndrome," Clinical Immunology, vol. 139, no. 3, pp. 314-320, 2011.

[22] X. S. Shao, X. Q. Yang, X. D. Zhao et al., "The prevalence of Th17 cells and FOXP3 regulate T cells (Treg) in children with primary nephrotic syndrome," Pediatric Nephrology, vol. 24, no. 9, pp. 1683-1690, 2009.

[23] S. S. Hue, S. M. Suhail, J. C. J. Choo et al., "Do Foxp3+ regulatory T cells (treg cells) play a role in the immunopathogenesis of primary/idiopathic minimal change disease?" ISRN Pathology, vol. 2014, 8 pages, 2014.

[24] D. B. Ascon, M. Ascon, S. Satpute et al., "Normal mouse kidneys contain activated and CD3+CD4-CD8- double-negative T lymphocytes with a distinct TCR repertoire," Journal of Leukocyte Biology, vol. 84, no. 6, pp. 1400-1409, 2008.

[25] J. Strehlau, A. D. Schachter, M. Pavlakis, A. Singh, A. Tejani, and T. B. Strom, "Activated intrarenal transcription of CTL-effectors and TGF-[beta]1 in children with focal segmental glomerulosclerosis," Kidney International, vol. 61, no. 1, pp. 90-95, 2002.

Francisco Salcido-Ochoa, (1,2) Susan Swee-Shan Hue, (1,3) Doreen Haase, (4,5) Jason Chon Jun Choo, (2) Nurhashikin Yusof, (5) Reiko Lixiang Li, (6) John Carson Allen Jr., (7) Jabed Iqbal, (8) Alwin Hwai Liang Loh, (8) and Olaf Rotzschke (5)

(1) Tregs and HLA Research Force, Singapore General Hospital, The Academia, 20 College Road, Singapore 169856

(2) Renal Medicine Department, Singapore General Hospital, The Academia, 20 College Road, Singapore 169856

(3) Department of Pathology, National University Hospital, 5 Lower Kent Ridge Road, Singapore 119074

(4) Kompetenznetz Vorhofflimmern e.V. (AFNET), Miinster, Germany

(5) Singapore Immunology Network (SIGN), Agency for Science, Technology and Research (A'STAR), Biopolis, Singapore

(6) Department of Pathology and Laboratory Medicine, KK Women's and Children's Hospital, 100 Bukit Timah Road, Singapore 229899

(7) Centre for Quantitative Medicine, Duke-NUS Graduate Medical School, The Academia, 20 College Road, Singapore 169856

(8) Department of Pathology, Singapore General Hospital, The Academia, 20 College Road, Singapore 169856

Correspondence should be addressed to Francisco Salcido-Ochoa; francisco.salcido.ochoa@singhealth.com.sg

Received 16 March 2017; Revised 15 May 2017; Accepted 14 June 2017; Published 15 August 2017

Academic Editor: Jochen Reiser

Caption: FIGURE 1: Detection of different lymphocyte and T cell subsets infiltrating kidney tissue in a patient with primary MCD with a mild-moderate infiltrate, using antibodies to CD4, CD8, CD19, granzyme B, IL-17, and Foxp3 as labelled on the pictures. An area with a significant infiltrate was selected for display purposes (200x magnification). The inlets on the lower right corner of each single-staining slide show a higher magnification (400x) of selected regions (small squares) to enhance visualization of marker-positive cells [immunohistochemistry staining using peroxidase conjugated antibodies].

Caption: FIGURE 2: (a) Percentage of cortex infiltration of [CD8.sup.+] T cells, [CD4.sup.+] T cells, and [CD19.sup.+] B cells in kidney tissue of 9 patients with primary MCD. (b) Cell densities of the infiltrating [Foxp3.sup.+] Treg cells, [IL- 17.sup.+] Th17 cells, and granzyme B+ cytotoxic cells in kidney tissue of these primary MCD patients. (c) Ratios of the cell densities of Th17 cells over [Foxp3.sup.+] Treg cells and cytotoxic cells over Treg cells, infiltrating kidney tissue of primary MCD patients (the horizontal black line indicates the arbitrary ratio reference value of 1; the red arrows indicate the direction of the ratios, increased or decreased). Cells were detected by immunohistochemistry, and the median percentages, cell densities, and their ratios are reported.

Caption: FIGURE 3: Representative surrogate T cell subsets in peripheral blood of a patient with primary MCD. [CD4.sup.+][CD25.sup.+][Foxp3.sup.+] Treg cells (a), [CD4.sup.+][D161.sup.+] Th17 cells (b), [CD4.sup.+][D45RA.sup.-] memory T cells (c), [CD4.sup.+][D45RA.sup.+] naive T cells (d), [CD8.sup.+][D45RA.sup.-] memory T cells (e), [CD8.sup.+][D45RA.sup.+] naive T cells (f), [CD3.sup.+][D56.sup.+] NKT cells (g), [CD3.sup.-][D56.sup.+] NK cells (h), [CD3.sup.+][CRd1.sup.+] gamma-delta T cells (i), [CD3.sup.+][CRd2.sup.+] gamma-delta T cells (j), and [CD4.sup.-][D161.sup.+][CRa7.2.sup.+] MAIT cells (k) were detected by 20-colour flow cytometry, using the appropriate antibodies as described in the methods section.

Caption: FIGURE 4: Comparative circulating cell numbers per microlitre of blood and comparative percentages from total lymphocytes of circulating total [CD3.sup.+] T cells (a, b), total [CD4.sup.+] T cells (c, d), naive [CD4.sup.+][D45RA.sup.+] T cells (g, h), memory [CD4.sup.+][D45RA.sup.-] T cells (k, l), total [CD8.sup.+] T cells (e, f), naive [CD8.sup.+][D45RA.sup.+] T cells (i, j), memory [CD8.sup.+][D45RA.sup.-] T cells (m, n), [CD4.sup.+][D25.sup.+][Foxp3.sup.+] Treg cells (o, p), and [CD4.sup.+][CD161.sup.+] Th17 cells (q, r) between 7 primary MCD patients and up to 12 healthy controls. Cells were detected by 20-colour fluorescence-activated flow cytometry. The median cell numbers are represented by the horizontal lines. The asterisks indicate that the comparisons were statistically significant and the respective p value is given.

Caption: FIGURE 5: Comparative circulating cell numbers per microlitre of blood and comparative percentages from total lymphocytes of circulating [CD19.sup.+] B cells (a, b), monocytes (c, d), [CD3.sup.+][TCRd1.sup.+] gamma- delta T cells (e, f), [CD3.sup.+][TCRd2.sup.+] gamma-delta T cells (g, h), [CD3.sup.+][CD56.sup.+] NKT cells (i, j), [CD4.sup.-][CD161.sup.+][TCRa7.2.sup.+] MAIT cells (k, l), and [CD3.sup.-][CD56.sup.+] NK cells (m, n) between up to 8 primary MCD patients and up to 12 healthy controls. Cells were detected by 20-colour fluorescence-activated flow cytometry. The median cell numbers are represented by the horizontal lines. The asterisks indicate that the comparisons were statistically significant and the respective p value is given.

Caption: FIGURE 6: Comparative ratios of circulating Th17 cells over Treg cells (a) and memory [CD8.sup.+] T cells over Treg cells (b) between 7 primary MCD patients and 3 healthy controls. Cells were detected by 20-colour fluorescence- activated flow cytometry. The median ratios are represented by the horizontal lines. The comparisons did not reach statistical significance.

Caption: FIGURE 7: Time to complete remission of the 9 patients with primary MCD. The median time to complete remission was 28 days.

Caption: FIGURE 8: Selected correlation plots between lymphocyte and T cell subsets and clinical outcomes at disease onset in primary MCD. This figure is supplementary to Table 3, where the complete list of statistically significant correlations between outcomes and other disease subsets is found. Only the comparisons that were (1) statistically significant, (2) related to outcomes at disease onset (t0), (3) related to our original hypothesis that the immune balance in MCD is tilted towards a dominance of Th17 and cytotoxic cells over the [Foxp3.sup.+] Treg subset, and (4) discussed in the text are plotted here for visual reference. Correlations plotted: number of circulating [CD8.sup.+] T cells with serum creatinine (a); number of circulating [CD8.sup.+] T cells with MDRD GFR (b); percentage of kidney tissue infiltrating [CD4.sup.+] T cells with proteinuria (c); percentage of circulating naive [CD8.sup.+] T cells with proteinuria (d); and ratio of tissue cytotoxic over [Foxp3.sup.+] Treg cells with MDRD GFR (e).
TABLE 1: Baseline clinical and demographic characteristics of the
patients with primary MCD.

n                                    9

Age (years) *                       31.4
Male sex (#)                        6/9
Race, Chinese (#)                   8/9
Diabetes mellitus (#)               1/9
GFR at biopsy (ml/min/1.73 m2) *    83.6
Proteinuria at biopsy (g/day) *     7.46
Albumin (g/L)*                       15
Steroids use at biopsy (#)          2/9
MMF or AZA use at biopsy (#)        0/9
Cytotoxics use at biopsy (#)        0/9

AZA: azathioprine; GFR: glomerular filtration rate; MMF:
mycophenolate mofetil. * Results reported as median values.

TABLE 2: Summary of the clinical characteristics and outcomes of the
patients with primary MCD.

Patient   Age/sex    Race     Diabetes     GFR      GFR last
                              mellitus   at onset   follow-up

1          25/F     Chinese      No       167.8       132.2
2          52/M     Chinese      No        73.9       93.4
3          31/M     Indian       No        48.7       96.7
4          21/M     Chinese      No        17.7       77.9
5          47/F     Chinese      No       132.9       132.9
6          21/F     Chinese      No        83.6       84.4
7          25/F     Chinese      No       146.4       115.4
8          62/M     Chinese      No        84.8       57.3
9          65/M     Chinese     Yes        14.0       67.6

Patient   Proteinuria   Proteinuria   Albumin    Steroids
            at onset       last       at onset   at biopsy
                         follow-up

1             7.9          0.16          17         No
2             5.6           0.1         9.0         No
3            10.3          0.05          13         No
4             7.5           0.1         15.0        No
5            13.7          13.7         14.0        No
6             5.0           0.1         15.0        Yes
7             6.0           0.0         17.0        Yes
8             3.4           0.3         30.0        No
9            14.0          14.4         20.0        No

Patient       Days         Total
          to complete     days of
           remission     follow-up

1             356          1385

2             25.0         1320
3              20          1364
4              97          1256
5             UNK            1
6              6           1197
7             20.0          298
8              31          1102
9             343           925

F: female; GFR: glomerular filtration rate; M: male; MCD: minimal
change disease; UNK: unknown due to loss of follow-up.

TABLE 3: Correlation between lymphocyte and T cell subsets and
clinical outcomes in primary MCD.

Immune cell parameter     versus      Clinical         R      p value
                                       outcome

Circulating total CD8+                  Serum          1      0.0004
T cells (#)                         creatinine t0

Circulating memory CD8+                 Serum       -0.9429   0.0167
T cells (%)                         creatinine t6

Circulating total CD8+                  Serum       0.9276    0.0167
T cells (#)                          creatinine
                                         t12

Circulating monocytes                   Serum       0.7545    0.0377
(#)                                  creatinine
                                         t12

Circulating memory CD4+                 Serum         -1      0.0167
T cells (#)                          creatinine
                                         t24

Circulating memory CD4+                 Serum       -0.9747   0.0333
T cells (#)                          creatinine
                                         t36

Circulating total CD8+                 GFR t0       -0.9286   0.0067
T cells (#)

Tissue cytotoxic/Treg                  GFR t0       -0.7197   0.0342
ratio

Circulating Th17 cells                 GFR t6       0.8986    0.0278
(%)

Blood Th17/Treg ratio                  GFR t6       0.8986    0.0278

Circulating monocytes                  GFR t6       -0.7306   0.0476
(#)

Circulating monocytes                  GFR t12      -0.8333   0.0154
(#)

Circulating naive CD4+                 GFRt36       1.0000    0.0167
T cells (%)

Circulating naive CD4+                 GFRt36       1.0000    0.0167
T cells (%)

Circulating naive CD8+               Proteinuria    0.7857     0.048
T cells (%)                              t0

Infiltrating CD4+ T                  Proteinuria    0.7668    0.0254
cells (%)                                t0

Circulating TCRgd2+ T                Proteinuria    0.7857     0.048
cells (%)                                t6

Circulating monocytes                Proteinuria    0.8095    0.0218
(%)                                      t6

Circulating monocytes                Proteinuria    0.7619    0.0368
(#)                                      t12

Circulating total CD3+               Proteinuria    -0.9747   0.0333
T cells (%)                              t24

Circulating Th17 cells               Proteinuria    -0.9747   0.0333
(%)                                      t36

Circulating Th17 cells               Proteinuria    -0.9747   0.0333
(#)                                      t36

Blood Th17/Treg ratio                Proteinuria    -0.9747   0.0333
                                         t36

Tissue cytotoxic/Treg                Proteinuria    -0.8407   0.0444
ratio                                    t36

Circulating TCRgd2+ T                  Time to      0.8469    0.0238
cells (%)                             complete
                                      remission

Circulating TCRgd2+ T                  Time to      0.7748    0.0492
cells (#)                             complete
                                      remission

Circulating monocytes                  Time to      0.8368    0.0072
(%)                                   complete
                                      remission

Circulating monocytes                  Time to      0.8201    0.0095
(#)                                   complete
                                      remission
COPYRIGHT 2017 COPYRIGHT 2010 SAGE-Hindawi Access to Research
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Salcido-Ochoa, Francisco; Hue, Susan Swee-Shan; Haase, Doreen; Choo, Jason Chon Jun; Yusof, Nurhashi
Publication:International Journal of Nephrology
Date:Jan 1, 2017
Words:7017
Previous Article:Comparative Performance of Creatinine-Based Estimated Glomerular Filtration Rate Equations in the Malays: A Pilot Study in Tertiary Hospital in...
Next Article:Focused Real-Time Ultrasonography for Nephrologists.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters